$0.340
-0.000 (-0.09%)終値時点
DYAI のニュース
DYAI のイベント
Selling Stockholders Plan to Sell Up to 3.625M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.625M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Dyadic International Completes $2.9M Stock Offering
Dyadic International announced definitive agreements with an institutional investor for the purchase and sale of shares of Common Stock in a registered direct offering with a concurrent private placement of warrants to the same investor. Aggregate gross proceeds to the company from both transactions are expected to be approximately $2.9M. The offering price per share of Common Stock is 79.5c and per Warrant is $0.005. The transactions consisted of the sale of 3.625M shares of Common Stock in the registered direct offering and Common Warrants to purchase 3.625M shares of Common Stock in the private placement with an exercise price of 84c per share. Aggregate gross proceeds to the company are expected to be approximately $2.9M. The transactions are expected to close on or about August 14, subject to the satisfaction of customary closing conditions. Aegis Capital Corp. is acting as exclusive placement agent for the offerings.
Dyadic International Expands Non-Animal Dairy Pipeline
Dyadic International announced the expansion of its commercial non-animal dairy pipeline through a new development and commercial license agreement with a European biotechnology company for additional precision-fermented dairy proteins. The agreement further expands Dyadic's growing food and nutrition pipeline while reinforcing the company's strategy of developing recurring revenue opportunities through strategic development partnerships, licensing and commercial participation.
Dyadic International Expands Bio-Industrial Pipeline
Dyadic International announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program focused on advanced cellulose processing. "We see this program as a key step in expanding our bio-industrial portfolio," said Joe Hazelton, president and COO of Dyadic Applied BioSolutions. "Following the launch of EN3ZYME, we continue to leverage the Dapibus platform to develop differentiated enzyme solutions for attractive industrial markets. Each new program further reinforces the scalability of the platform and strengthens our ability to drive value through proprietary products, strategic collaborations and licensing. Our goal is to build a diversified portfolio that supports long-term growth".
Dyadic International Collaborates with Scripps Research to Evaluate Hantavirus Antibodies
Dyadic International announced that Dyadic Applied BioSolutions and researchers at Scripps Research are collaborating to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, a hantavirus strain associated with Hantavirus Pulmonary Syndrome. The company said, "A series of recently reported hantavirus and Ebola cases worldwide have underscored the importance of pandemic preparedness and highlighted the need to improve the speed, scalability, flexibility, and cost-effectiveness of biologic manufacturing during rapidly evolving public health events. The collaboration builds upon Dyadic's prior Andes virus monoclonal antibody work and combines the complementary expertise of Dyadic and Scripps Research to further assess the potential of Dyadic's proprietary C1 platform for rapid development timelines, high-productivity microbial fermentation, large-scale manufacturing, and biologic production intended to support future infectious disease preparedness."
関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。